GC101 cell therapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests GC101, a new cell-based treatment for non-small cell lung cancer in patients who have already tried other targeted drugs. The trial involves surgically removing some tumor tissue to grow immune cells in the lab, then infusing them back into your body to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Diagnosis of non-small cell lung cancer without EGFR, ALK, or ROS-1 mutations
- Previous treatment with at least one targeted therapy (if you have other genetic mutations like KRAS G12C) and chemotherapy that stopped working
- A surgically removable tumor piece (>150 mm³) that hasn't been treated with radiation or other local therapies
- Good overall health (ECOG 0–1) with no uncontrolled heart, liver, or lung disease
- Willingness to use contraception for 1 year after cell infusion and ability to have surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
This trial tests GC101 tumor-infiltrating lymphocytes (TILs), which are special immune cells collected from a tumor, grown in a lab, and given back to treat gastrointestinal cancers that have returned or spread. It may help your immune system better attack the cancer, especially when standard treatments have not worked.
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.